FDA 483 - George A. Diaz, M.D. - July 17, 2020

An FDA inspection of George A. Diaz, MD, Infectious Disease Hospitalist in Everett, WA, revealed a significant deficiency in conducting an investigation. The firm failed to report a serious adverse event (SAE) within the timeframe specified by the protocol and investigational plan. This lapse involved a subject experiencing a potentially life-threatening decrease in estimated glomerular filtration rate (eGFR).